CatalystFDA/Bio

Vaxcyte is up ~32% after phase 3 topline data for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. The OPUS-1 trial was designed to test non-inferiority and immunogenicity against Merck

Vaxcyte jumps on positive Phase 3 data for VAX-31 pneumonia vaccine.

PCVX

$63.68

+0.09%

MRK

$143.63

-1.59%

What changed

Vaxcyte jumps on positive Phase 3 data for VAX-31 pneumonia vaccine.

Why it matters

Vaxcyte jumps on positive Phase 3 data for VAX-31 pneumonia vaccine. — impact context not separately stored; see What changed.

Sources